MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Open accessPublished version of a preprint
Abstract
The phosphoinositide 3-kinase (PI3K)/AKT and RAF/MEK/ERK signaling pathways are activated in a wide range of human cancers. In many cases, concomitant inhibition of both pathways is necessary to block proliferation and induce cell death and tumor shrinkage. Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a parallel signaling pathway, thereby decreasing the effectiveness of single-agent targeted therapies. In this study, we describe a feedback mechanism in which MEK inhibition leads to activation of PI3K/AKT signaling in EGFR and HER2-driven cancers. We found that MEK inhibitor–induced activation of PI3K/AKT resulted from hyperactivation of ERBB3 as a result of the loss of an inhibitory threonine phosphorylation in the conserved juxtamembrane domains of EGFR and HER2. Mutation of this amino acid led to increased ERBB receptor activation and upregulation of the ERBB3/PI3K/AKT signaling pathway, which was no longer responsive to MEK inhibition. Taken together, these results elucidate an important, dominant feedback network regulating central oncogenic pathways in human cancer. Cancer Res; 72(13); 3228–37. ©2012 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibition of either PI3K/mTOR or ERK signaling often relieves feedback inhibition of the other and causes its activation.
“Inhibition of either PI3K/mTOR or ERK signaling often relieves feedback inhibition of the other and causes its activation46,47.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [47]
In NSCLCs and CRCs, KRASG12C inhibition leads to accumulation of activated upstream EGFR and/or other ERBB family members, facilitating escape from KRASG12C-inhibitor monotherapy.
“In NSCLCs and CRCs, KRASG12C inhibition leads to an accumulation of activated upstream EGFR and/or other ERBB family members, which facilitates escape from KRASG12C-inhibitor monotherapy110,121–124.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · see citing works
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600 · see citing works
Self-citationmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works
Self-citationPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · see citing works
Self-citationAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · see citing works
Sun, S., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 800 · see citing works
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Jura, N., Endres, N., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 609 · see citing works
Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D. J., Brandhuber, B. J., Gross, S. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578 · see citing works
Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 533 · see citing works
Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 494 · see citing works
Self-citationHoeflich, K. P., O'Brien, C. L., Boyd, Z. S., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H. M., Punnoose, E. A., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 467 · see citing works
Targeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C. O., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 466 · see citing works
Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457 · see citing works
Self-citationCharacterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
Dibble, C. C., Asara, J. M., & Manning, B. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00735-09 · Cited by 420 · see citing works
Self-citationMirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D. R., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 387 · see citing works
Zheng, B., Jeong, J. H., Asara, J. M., Yuan, Y.-Y., Granter, S. R., Chin, L., & Cantley, L. C. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.026 · Cited by 355 · see citing works
Self-citationChakrabarty, A., Sanchez, V. M., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347 · see citing works
Self-citationDifferential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Faber, A. C., Li, D., Song, Y., Liang, M., Yeap, B. Y., Bronson, R. T., Lifshits, E., Zhao, C., Maira, S.-M., Garcı́a-Echeverrı́a, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 315 · see citing works
Self-citationThe Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
Brewer, M. R., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., & Carpenter, G. F. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.034 · Cited by 314 · see citing works
Ono, M., Hirata, A., Kometani, T., Miyagawa, M., Ueda, S.-I., Kinoshita, H., Fujii, T., & Kuwano, M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.465.3.4 · Cited by 305 · see citing works
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. E. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 282 · see citing works
Self-citationTargeting HER proteins in cancer therapy and the role of the non-target HER3
Hsieh, A. C., & Moasser, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603910 · Cited by 269 · see citing works
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210 · see citing works
Self-citationNorthwood, I. C., Gonzalez, F. A., Wartmann, M., Raden, D. L., & Davis, R. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98612-6 · Cited by 209 · see citing works
Takishima, K., Griswold‐Prenner, I., Ingebritsen, T. S., & Rosner, M. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2520 · Cited by 159 · see citing works
Yu, C. F., Liu, Z., & Cantley, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200732200 · Cited by 149 · see citing works
An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels
Diamonti, A. J., Guy, P. M., Ivanof, C., Wong, K., Sweeney, C. A., & Carraway, K. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052709799 · Cited by 126 · see citing works
Li, X., Huang, Y., Jiang, J., & Frank, S. J. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.08.006 · Cited by 111 · see citing works
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
Carracedo, A., Baselga, J. M., & Pandolfi, P. P. (2008) · Cell Cycle · doi:10.4161/cc.7.24.7244 · Cited by 80 · see citing works
Yoon, Y., Kim, H., Han, S., Hur, H.-S., Oh, D. Y., Im, S., Bang, Y., & Kim, T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0300 · Cited by 71 · see citing works
Faber, A. C., Dufort, F. J., Blair, D., Wagner, D. J., Roberts, M. F., & Chiles, T. C. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.009 · Cited by 68 · see citing works
Identification of Major ERK-Related Phosphorylation Sites in Gab1
Lehr, S., Kotzka, J., Avci, H., Sickmann, A., Meyer, H. E., Herkner, A., & Müller‐Wieland, D. (2004) · Biochemistry · doi:10.1021/bi049753e · Cited by 61 · see citing works
Modeling oncogene addiction using RNA interference
Rothenberg, S. M., Engelman, J. A., Le, S., Riese, D. J., Haber, D. A., & Settleman, J. E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803217105 · Cited by 47 · see citing works
Self-citationE3 ubiquitin ligases in ErbB receptor quantity control
Carraway, K. L. (2010) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2010.09.006 · Cited by 45 · see citing works
Activated ERK2 Interacts with and Phosphorylates the Docking Protein GAB1
Roshan, B., Kjelsberg, C., Spokes, K., Eldred, A., Crovello, C. S., & Cantley, L. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36362 · Cited by 36 · see citing works
The Juxtamembrane Region of EGFR Takes Center Stage
Hubbard, S. R. (2009) · Cell · doi:10.1016/j.cell.2009.06.008 · Cited by 30 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027 · see citing works
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · see citing works
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works
Self-citationA Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940 · see citing works
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works
The PI3K/AKT/mTOR interactive pathway
Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015) · Molecular BioSystems · doi:10.1039/c5mb00101c · Cited by 683 · see citing works
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · see citing works
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 638 · see citing works
Negative feedback regulation of the ERK1/2 MAPK pathway
Lake, D., Corrêa, S. A. L., & Müller, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2297-8 · Cited by 565 · see citing works
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works
Hu, K., Li, K., Lv, J., Feng, J., Chen, J., Wu, H., Cheng, F., Jiang, W., Wang, J., Pei, H., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124049 · Cited by 409 · see citing works
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 396 · see citing works
Rozengurt, E., Soares, H. P., & Sinnet-Smith, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0330 · Cited by 316 · see citing works
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 261 · see citing works
Self-citationPI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 212 · see citing works
ERKs in Cancer: Friends or Foes?
Deschênes‐Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 210 · see citing works
Ras and Rap1: A tale of two GTPases
Shah, S. K., Brock, E. J., Ji, K., & Mattingly, R. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 210 · see citing works
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer
Tricker, E. M., Xu, C., Uddin, S., Capelletti, M., Ercan, D., Ogino, A., Pratilas, C. A., Rosen, N. X., Gray, N. S., Wong, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0063 · Cited by 207 · see citing works
Learning single-cell perturbation responses using neural optimal transport
Bunne, C., Stark, S. G., Gut, G., del Castillo, J. S., Levesque, M., Lehmann, K.-V., Pelkmans, L., Krause, A., & Rätsch, G. (2023) · Nature Methods · doi:10.1038/s41592-023-01969-x · Cited by 202 · see citing works
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
Gibney, G. T., Messina, J. L., Smalley, I., Sondak, V. K., & Smalley, K. S. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.83 · Cited by 194 · see citing works
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177 · see citing works
MEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 189 · see citing works
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177 · see citing works
Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176 · see citing works
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J. M., & Piccart, M. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 177 · see citing works
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Leary, M., Heerboth, S., LAPINSKA, K., & Sarkar, S. (2018) · Cancers · doi:10.3390/cancers10120483 · Cited by 166 · see citing works
Miller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 163 · see citing works
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155 · see citing works
Dumble, M. L., Crouthamel, M., Zhang, S., Schaber, M. D., Levy, D. S., Robell, K. A., Liu, Q., Figueroa, D. J., Minthorn, E. A., Seefeld, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100880 · Cited by 150 · see citing works
Targeting PI3K Signaling in Combination Cancer Therapy
Tostivint, E. P., Thibault, B., & Guillermet‐Guibert, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.002 · Cited by 141 · see citing works
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D. E., Lin, J., Reddy, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000305 · Cited by 139 · see citing works
Roberts, P. J., Usary, J., Darr, D. B., Dillon, P. M., Pfefferle, A. D., Whittle, M. C., Duncan, J. S., Johnson, S. M., Combest, A. J., Jin, J. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0563 · Cited by 138 · see citing works
Do, K. T., Speranza, G., Bishop, R. J., Khin, S. A., Rubinstein, L., Kinders, R. J., Datiles, M. B., Eugeni, M. A., Lam, M. H., Doyle, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0212-z · Cited by 133 · see citing works
Butler, D. E., Marlein, C. R., Walker, H. F., Frame, F. M., Mann, V. M., Simms, M. S., Davies, B. R., Collins, A. T., & Maitland, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18082 · Cited by 135 · see citing works
Targeting RAS-mutant cancers: is ERK the key?
Ryan, M. B., Der, C., Wang-Gillam, A., & Cox, A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 125 · see citing works
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123 · see citing works
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 123 · see citing works
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Temraz, S., Mukherji, D., & Shamseddine, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922976 · Cited by 117 · see citing works
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas
Konstantinidou, G., Ramadori, G., Torti, F., Kangasniemi, K., Ramirez, R. E., Cai, Y., Behrens, C., Dellinger, M. T., Brekken, R. A., Wistuba, I. I., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0388 · Cited by 114 · see citing works
Ammad-ud-din, M., Khan, S. A., Malani, D., Murumägi, A., Kallioniemi, O., Aittokallio, T. A., & Samuel Kaski, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw433 · Cited by 118 · see citing works
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
Jokinen, E., & Koivunen, J. P. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015571111 · Cited by 116 · see citing works
AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Zuo, Q., Liu, J., Huang, L., Qin, Y., Hawley, T. S., Seo, C., Merlino, G. T., & Yu, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0205-4 · Cited by 110 · see citing works
RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Nicolantonio, F. D., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 109 · see citing works
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V. M., Xu, L., Kohli, N., Rennard, R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 103 · see citing works
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Triulzi, T., Forte, L., Regondi, V., Modica, M. D., Ghirelli, C., Carcangiu, M. L., Sfondrini, L., Balsari, A., & Tagliabue, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512942 · Cited by 102 · see citing works
Smith, T., Affram, K., Nottingham, E., Han, B., Amissah, F., Krishnan, S., Trevino, J. G., & Agyare, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-73218-6 · Cited by 98 · see citing works
Xia, G., Wang, H., Song, Z., Meng, Q., Huang, X., & Huang, X. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0579-0 · Cited by 98 · see citing works
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
Wang, J., Hu, K., Guo, J., Cheng, F., Lv, J., Jiang, W., Lü, W., Liu, J., Pang, X., & Liu, M. (2016) · Nature Communications · doi:10.1038/ncomms11363 · Cited by 96 · see citing works
Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00776-6 · Cited by 90 · see citing works
Shiau, J., Chuang, Y.-T., Tang, J., Yang, K., Chang, F., Hou, M., Yen, C., & Chang, H. (2022) · Antioxidants · doi:10.3390/antiox11091845 · Cited by 94 · see citing works
Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80 · see citing works
Carter, C. A., Rajan, A., Keen, C., Szabo, E. M., Khozin, S., Thomas, A., Brzezniak, C. E., Guha, U., Doyle, L. A., Steinberg, S. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw008 · Cited by 89 · see citing works
Cushman, S. M., Jiang, C., Hatch, A. J., Shterev, I. D., Sibley, A. B., Niedzwiecki, D., Venook, A. P., Owzar, K., Hurwitz, H. I., & Nixon, A. B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2313 · Cited by 84 · see citing works
Pettazzoni, P., Viale, A., Shah, P. K., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 80 · see citing works
Mazumdar, T., Byers, L. A., Ng, P. K. S., Mills, G. B., Peng, S., Diao, L., Fan, Y.-H., Stemke‐Hale, K., Heymach, J. V., Myers, J. N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1090 · Cited by 79 · see citing works
Sanlorenzo, M., Choudhry, A., Vujic, I., Posch, C., Kim, C. A., Johnston, K., Meier, M. M., Osella‐Abate, S., Quaglino, P., DAUD, A. I., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.09.002 · Cited by 77 · see citing works
Bahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 74 · see citing works
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
Sandhöfer, N., Metzeler, K. H., Rothenberg, M., Herold, T., Tiedt, S., Groiß, V., Carlet, M., Walter, G., Hinrichsen, T., Wachter, O., et al. (2014) · Leukemia · doi:10.1038/leu.2014.305 · Cited by 75 · see citing works
MEK inhibitors under development for treatment of non-small-cell lung cancer
Kim, C. G., & Giaccone, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1415324 · Cited by 73 · see citing works
Fu, X., Creighton, C. J., Biswal, N. C., Kumar, V., Shea, M. J., Herrera, S., Contreras, A., Gutiérrez, C., Wang, T., Nanda, S., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0430-x · Cited by 72 · see citing works
Adaptive stress signaling in targeted cancer therapy resistance
Pazarentzos, E., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.26 · Cited by 71 · see citing works
Vakana, E., Pratt, S. E., Blosser, W. D., Dowless, M. S., Simpson, N., Yuan, X., Jaken, S., Manro, J. R., Stephens, J. R., Zhang, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14002 · Cited by 70 · see citing works
Gendelman, R., Xing, H., Mirzoeva, O. K., Sarde, P., Curtis, C. N., Feiler, H. S., MCDONAGH, P. D., Gray, J. W., Khalil, I. G., & Korn, W. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0512 · Cited by 70 · see citing works
Sato, H., Yamamoto, H., Sakaguchi, M., Shien, K., Tomida, S., Shien, T., Ikeda, H., Hatono, M., Torigoe, H., Namba, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13763 · Cited by 71 · see citing works
Ponz‐Sarvisé, M., Corbo, V., Tiriac, H., Engle, D. D., Frese, K. K., Oni, T. E., Hwang, C., Öhlund, D., Chio, I. I. C., Baker, L. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1398 · Cited by 63 · see citing works
Choi, C., & Helfman, D. M. (2013) · Oncogene · doi:10.1038/onc.2013.341 · Cited by 65 · see citing works
Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells
Chivu‐Economescu, M., Dragu, D., Necula, L. G., Matei, L., Enciu, A., Bleoţu, C., & Diaconu, C. C. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0712-y · Cited by 65 · see citing works
Chen, C., Hsia, T., Yeh, M., Chen, T.-H., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12102 · Cited by 65 · see citing works
Spreafico, A., Tentler, J. J., Pitts, T. M., Tan, A. C., Gregory, M. A., Arcaroli, J. J., Klauck, P. J., McManus, M. C., Hansen, R. J., Kim, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3140 · Cited by 64 · see citing works
Rocca, A., Braga, L., Volpe, M. C., Maiocchi, S., & Generali, D. (2022) · Cancers · doi:10.3390/cancers14215306 · Cited by 65 · see citing works
Interleukin‐1β orchestrates underlying inflammatory responses in microglia via Krüppel‐like factor 4
Kaushik, D. K., Thounaojam, M. C., Kumawat, K. L., Gupta, M., & Basu, A. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12382 · Cited by 63 · see citing works
Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer
Ludwik, K. A., Campbell, J. P., Li, M., Li, Y., Sandusky, Z. M., Pasic, L., Sowder, M. E., Brenin, D. R., Pietenpol, J. A., O'Doherty, G. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0106 · Cited by 63 · see citing works
Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells
Wu, K., Chang, Q., Lu, Y., Qiu, P., Chen, B., Thakur, C., Sun, J., Li, L., Kowluru, A., & Chen, F. (2013) · Oncotarget · doi:10.18632/oncotarget.1431 · Cited by 62 · see citing works
Wu, L. Y., Maachani, U. B., Schweitzer, M. E., Singh, R., Wang, M., Chang, R. Y., & Souweidane, M. M. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.12.008 · Cited by 61 · see citing works
McNeill, R. S., Canoutas, D. A., Stuhlmiller, T. J., Dhruv, H., Irvin, D., Bash, R., Angus, S. P., Herring, L. E., Simon, J. M., Skinner, K., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox044 · Cited by 61 · see citing works
Ewald, F., Nörz, D. S., Grottke, A., Hofmann, B. T., Nashan, B., & Jücker, M. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0149-7 · Cited by 60 · see citing works
Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Flanigan, S. A., Pitts, T. M., Newton, T. P., Kulikowski, G. N., Tan, A. C., McManus, M. C., Spreafico, A., Kachaeva, M. I., Selby, H. M., Tentler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0145 · Cited by 57 · see citing works
New strategies for targeting kinase networks in cancer
Yesilkanal, A. E., Johnson, G. L., Ramos, A. F., & Rosner, M. R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101128 · Cited by 55 · see citing works
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Miyabayashi, K., Ijichi, H., Mohri, D., Tada, M., Yamamoto, K., Asaoka, Y., Ikenoue, T., Tateishi, K., Nakai, Y., Isayama, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1453 · Cited by 57 · see citing works
Zañudo, J. G. T., Scaltriti, M., & Albert, R. (2017) · Cancer Convergence · doi:10.1186/s41236-017-0007-6 · Cited by 55 · see citing works
Precision drugging of the MAPK pathway in head and neck cancer
Ngan, H.-L., Law, C.-H., Choi, Y., Chan, J., & Lui, V. W. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00293-1 · Cited by 51 · see citing works
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 56 · see citing works
Vena, F., Causi, E. L., Rodriguez‐Justo, M., Goodstal, S. M., Hagemann, T., Hartley, J. A., & Hochhauser, D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0485 · Cited by 54 · see citing works
Bianchi, A. S., Loupakis, F., Argilés, G., & Prager, G. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw191 · Cited by 54 · see citing works
The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
Mandel, A., Larsson, P., Sarwar, M., Semenas, J., Khaja, A. S. S., & Persson, J. L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0035-4 · Cited by 53 · see citing works
Recent advances in HER2-targeted delivery for cancer therapy
Dhritlahre, R. K., & Saneja, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.014 · Cited by 53 · see citing works
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 57 · see citing works
Yao, W.-L., Yue, P., Zhang, G.-J., Owonikoko, T., Khuri, F., & Sun, S.-Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.028 · Cited by 51 · see citing works
Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1
Xie, X., Tang, S.-C., Cai, Y., Pi, W., Deng, L., Wu, G., Chavanieu, A., & Teng, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11185 · Cited by 50 · see citing works
Umapathy, G., Guan, J., Gustafsson, D. E., Javanmardi, N., Cervantes-Madrid, D., Djos, A., Martinsson, T., Palmer, R. H., & Hallberg, B. (2017) · Science Signaling · doi:10.1126/scisignal.aam7550 · Cited by 50 · see citing works
Vetter, M. H., & Hays, J. L. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.01.012 · Cited by 50 · see citing works
SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics
del Río, I. B., Young, L. C., Sarı, S., Jones, G. G., Ringham-Terry, B., Hartig, N., Rejnowicz, E., Lei, W., Bhamra, A., Šurinová, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902658116 · Cited by 47 · see citing works
Kirouac, D. C., Du, J., Lahdenranta, J., Onsum, M. D., Nielsen, U. B., Schoeberl, B., & McDonagh, C. F. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004827 · Cited by 49 · see citing works
Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Chen, M., Peters, A., Huang, T., & Nan, X. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001152212 · Cited by 48 · see citing works
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer
Graham, D. M., Coyle, V. M., Kennedy, R. D., & Wilson, R. H. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0312-y · Cited by 47 · see citing works
Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer
He, Q., Xue, S., Tan, Y., Zhang, L., Shao, Q., Xing, L., Li, Y., Xiang, T., Luo, X., & Ren, G. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.004 · Cited by 47 · see citing works
Adaptive resistance to targeted therapies in cancer.
Rosell, R., Karachaliou, N., Morales-Espinosa, D., Costa, C., Molina‐Vila, M. Á., Sansano, I., Gascó, A., Viteri, S., Massutí, B., Wei, J., et al. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.08 · Cited by 48 · see citing works
Self-citationThe role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42 · see citing works
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Gillson, J., Ramaswamy, Y., Singh, G., Gorfe, A. A., Pavlakis, N., Samra, J. S., Mittal, A., & Sahni, S. (2020) · Cancers · doi:10.3390/cancers12051341 · Cited by 45 · see citing works
Schoumacher, M., Hurov, K. E., Lehár, J., Yan‐Neale, Y., Mishina, Y. M., Sonkin, D., Korn, J. M., Flemming, D., Jones, M. D., Antonakos, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0138-t · Cited by 44 · see citing works
- Authors
- Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., & Engelman, J. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Engelman, Jeffrey A.
- ORCID
- Venue
- Cancer Research
- Published
- 2012-07-01
- Volume
- 72
- Issue
- 13
- Pages
- 3228-3237
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3515079
- OpenAlex
- W2105437003
- Cited by
- 368
- References
- 37
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 22 · 2023: 30 · 2022: 32 · 2021: 21 · 2020: 27 · 2019: 25 · 2018: 27 · 2017: 30 · 2016: 36 · 2015: 25 · 2014: 30 · 2013: 18 · 2012: 3
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50 CA98131, R01 CA80195, P50CA127003, R01CA166480, U01CA141457, R01CA080195, R01CA140594, P50CA090578, K08CA120060, P50CA098131, P01CA120964, R01CA137008, P30CA006516)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- MEK inhibition, PI3K/Akt signaling, HER3, ErbB receptors, EGFR, HER2, negative feedback loop, Raf/MEK/ERK pathway, drug resistance, cancer pathways
- MeSH terms
- Cell Line, Enzyme Activation, Feedback, Flow Cytometry, Phosphatidylinositol 3-Kinases, Reverse Transcriptase Polymerase Chain Reaction, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinase Kinases, Proto-Oncogene Proteins c-akt, Tandem Mass Spectrometry, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
